SALT LAKE CITYŚResearchers at Huntsman Cancer Institute, in collaboration with a worldwide group of physicians and scientists, have discovered a remarkable treatment for a rare, yet debilitating, skin condition.
The study, published online November 24 in Molecular Therapy describes a new treatment for pachyonychia congenita, an ultra-rare genetic skin condition caused by mutations in a gene called keratin. The disorder is characterized by painful, blistering calluses on the feet and limbs that limit a patient's ability to walk. Other skin and nail problems also occur.
The new treatment involves a relatively new class of drug called siRNA, and works by preventing the gene with the mutation from being expressed but permitting the healthy keratin genes to function normally. The study marked the first time that the skin of a human subject was treated with this type of drug. Researchers say that in this single patient trial the drug worked, had no serious side effects, and has vast potential because of its ability to specifically and potently target single molecules, making it an option for many other genetic diseases, including cancer.
"The result is exceptionally promising since it suggests that siRNAs can be used safely on the skin and also possibly to treat genetic disorders that would otherwise have few therapeutic options," says Sancy Leachman, M.D., Ph.D., the study's lead author. "The patient was treated with siRNA on her right foot and with placebo on the left foot. The callus on the right foot that received the siRNA fell off at the site of injection, but this did not happen on the left foot."
Since the injections of the drug are particularly painful, the next step in the research will be to develop a more patient friendly, perhaps topical delivery of the medication.
This study marks a major collaborative accomplishment among international physicians, scientists, pharmaceutical companies, and charitable foundation members.
Leachman is an investigator at Huntsman Cancer Institute, a dermatologist, and an associate professor in the Department of Dermatology at the University of Utah.
The study's principal author, Sancy Leachman, MD is available for interviews. Photo and video opportunities are available, including slides of the skin condition and visuals of siRNA. To schedule an interview, contact the office of public affairs at 801-587-7639.
The mission of Huntsman Cancer Institute (HCI) at The University of Utah is to understand cancer from its beginnings, to use that knowledge in the creation and improvement of cancer treatments, to relieve the suffering of cancer patients, and to provide education about cancer risk, prevention, and care. HCI is a National Cancer Institute-designated cancer center, which means that it meets the highest national standards for cancer care and research and receives support for its scientific endeavors. HCI is also a member of the National Comprehensive Cancer Network (NCCN) a not-for-profit alliance of the world's leading cancer centers, which is dedicated to improving the quality and effectiveness of care provided to patients with cancer. For more information about HCI, please visit www.huntsmancancer.org.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.